Camrelizumab for injection | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Brand: Airuika
Company: Jiangsu Hengrui Pharmaceuticals
Medicine type: Biologic
Therapeutic area: Oncology
Indications recorded in the public source: Hepatocellular carcinoma: (1) advanced disease after sorafenib and/or lenvatinib and/or oxaliplatin-containing systemic chemotherapy; (2) with apatinib as first-line treatment of unresectable or metastatic disease. NSCLC: (1) with pemetrexed and carboplatin as first-line treatment of EGFR mutation-negative, ALK-negative unresectable locally advanced or metastatic nonsquamous NSCLC; (2) with paclitaxel and carboplatin as first-line treatment of locally advanced or metastatic squamous NSCLC. Esophageal squamous cell carcinoma: (1) locally advanced or metastatic disease that has progressed after or is intolerant of first-line chemotherapy; (2) with paclitaxel and cisplatin as first-line treatment of unresectable locally advanced, recurrent or metastatic disease. Nasopharyngeal carcinoma: (1) advanced disease that has progressed after or is intolerant of two or more lines of chemotherapy; (2) with cisplatin and gemcitabine as first-line treatment of locally recurrent or metastatic disease. Cervical cancer: (1) with famitinib for recurrent or metastatic disease after failure of platinum-based chemotherapy, without previous bevacizumab treatment; (2) with famitinib as first-line treatment of recurrent or metastatic PD-L1-positive disease (CPS >=1), confirmed using a fully validated test.
Indication source and scope: Source date(s): 2026-07-14, 2026-10-23. Manufacturer prescribing information for Mainland China. Evidence review: 23 October 2026.
Prescribing-information limitations: Complete official prescribing information obtained. Mainland China label. Original manufacturer page images have been preserved in order.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Market-by-market verification pending.
Insurance classification: Included in national insurance (Category B)
Insurance edition: 2025 edition; effective 1 January 2026
Insurance restrictions: Restricted to: (1) advanced hepatocellular carcinoma after sorafenib and/or lenvatinib and/or oxaliplatin-containing systemic chemotherapy; (2) use with pemetrexed and carboplatin as first-line treatment of EGFR mutation-negative, ALK-negative unresectable locally advanced or metastatic nonsquamous NSCLC; (3) locally advanced or metastatic esophageal squamous cell carcinoma that has progressed after or is intolerant of first-line chemotherapy; (4) advanced nasopharyngeal carcinoma that has progressed after or is intolerant of two or more lines of chemotherapy; (5) use with cisplatin and gemcitabine as first-line treatment of locally recurrent or metastatic nasopharyngeal carcinoma; (6) use with paclitaxel and cisplatin as first-line treatment of unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma; (7) use with paclitaxel and carboplatin as first-line treatment of locally advanced or metastatic squamous NSCLC; (8) use with apatinib mesylate as first-line treatment of unresectable or metastatic hepatocellular carcinoma; (9) use with famitinib malate for recurrent or metastatic cervical cancer previously treated with platinum-based chemotherapy but not bevacizumab.
Insurance period: 2026-01-01 to 2026-12-31
Insurance verification notes: Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

Sources

Open the interactive record, public price references and discussions